

vaccine safety and adverse reactions to vaccines.

Matters to be Discussed: The Subcommittee will discuss the inclusion of influenza and pneumococcal vaccines in the National Vaccine Injury Compensation Program summation, direction and closure; focus of safety subcommittees; and a review of report and recommendations from the Task Force on Safer Childhood Vaccines.

Name: NVAC Subcommittee on Immunization Coverage.

Time and Date: 1:30 p.m.–5 p.m., September 9, 1996.

Place: Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

Matters to be Discussed: The Subcommittee will discuss the forum on assessment and related immunization issues; the outline for the Subcommittee's report; and the assessment of immunization coverage.

Name: NVAC Subcommittee on Future Vaccines.

Time and Date: 1:30 p.m.–5 p.m., September 9, 1996.

Place: Hubert H. Humphrey Building, Room 405A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will develop policy options and guide the National Vaccine Program activities which will lead to development, licensure, and best use of new and existing vaccines in the simplest possible immunization schedules.

Matters to be Discussed: The Subcommittee will discuss updates on vaccine procurement strategies, the United States Agency for International Development vaccine research agenda, and a discussion of case studies in vaccine development.

Contact Person for More Information: Felecia D. Pearson, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639-7250.

This notice is being published less than 15 days prior to the meeting due to the inability to transmit the document electronically.

Dated: August 22, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-21924 Filed 8-27-96; 8:45 am]

BILLING CODE 4163-18-M

Health Resources and Services Administration

Advisory Council; Notice of Establishment

Pursuant to the Federal Advisory Committee Act, Public Law 92-463 (5 U.S.C. Appendix 2), the Secretary, Department of Health and Human Services announces the establishment of the following advisory council.

Designation: Advisory Committee to the Administrator, HRSA.

Purpose: Advises the Secretary of HHS and the Administrator of HRSA on policy matters pertinent to HRSA mission responsibilities in the conduct and support of health care delivery, health workforce, and related programs.

The committee may make recommendations concerning program development, resource allocation, and HRSA administrative practices and policies, and other specific matters which affect the operation of the Agency.

Structure: The Committee shall consist of the Secretary or designee as Chair and 16 members. Eleven members shall be authorities who are knowledgeable in the fields of health care delivery and finance, the health workforce and training of the workforce, public health, and the special needs of disadvantaged populations. Five members shall be representatives of the general public.

Dated: August 22, 1996.

Jackie E. Baum,

Advisory Committee Management Officer, HRSA.

[FR Doc. 96-21919 Filed 8-27-96; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

Notice of Meeting of the National Advisory Council for Human Genome Research

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Advisory Council for Human Genome Research, National Center for Human Genome Research, September 16-17, 1996, Holiday Inn, Washington/Chevy Chase, Palladian West/Center, 5522 Wisconsin Avenue, Chevy Chase, Maryland.

This meeting will be open to the public on Monday, September 16, from 8:30 to 1:00 p.m. to discuss administrative details or other issues relating to committee activities. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on September 16 from 1:00 p.m. to recess and on September 17 from 8:30 a.m. to adjournment, for the

review, discussion and evaluation of individual grant applications. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dr. Elke Jordan, Deputy Director, National Center for Human Genome Research, National Institutes of Health, Building 31, Room 4B09, Bethesda, Maryland 20892, (301) 496-0844, will furnish the meeting agenda, rosters of Committee members and consultants, and substantive program information upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Jane Ades, (301) 594-1229, two weeks in advance of the meeting.

(Catalog of Federal Domestic Assistance Program No. 93.172, Human Genome Research)

Dated: August 21, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-21897 Filed 8-27-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meetings of the National Cancer Advisory Board and its Subcommittee

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Cancer Advisory Board, National Cancer Institute, and its Subcommittees on September 10-11, 1996. Except as noted below, the meetings of the Board and its Subcommittees will be open to the public to discuss issues relating to committee business as indicated in the notice. Attendance by the public will be limited to space available.

A portion of the Board meeting will be closed to the public in accordance with the provisions set forth in secs. 552b(c)(4), 552b(c)(6), and 552(c)(9)(B), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, for the review, discussion and evaluation of individual grant applications and for discussion of issues pertaining to programmatic areas and/or NCI personnel, and discussion of subcommittee recommendations regarding NCI staff support to the Board and operating procedures. These applications and discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning the individuals associated